Medicare Coverage for Macular Degeneration: Eye Injections, Costs, and Why Medigap Matters

Age-related macular degeneration is the leading cause of vision loss in adults over 60 in the United States, and its primary treatment, monthly or bimonthly injections directly into the eye, is one of the more expensive recurring Medicare services many beneficiaries will encounter. These injections are covered under Medicare Part B as physician-administered drugs, not under Part D, which means the cost-sharing rules, the coverage mechanics, and the importance of supplemental coverage are quite different from what most people expect when they hear the word "drug."

Bryce's Take

AMD injections are one of the clearest cases where Medigap pays for itself. If you are getting monthly Eylea injections at a Part B cost of $1,500 to $2,000 each, that is 20% out of pocket without supplemental coverage, $300 to $400 per injection, potentially $3,600 to $4,800 per year on a single treatment. With Plan G, that is $0. For any client with AMD or significant family history, I weight the Medigap path heavily in our plan comparison.

Why AMD injections are Part B, not Part D

The anti-VEGF medications used to treat wet AMD, including aflibercept (Eylea), ranibizumab (Lucentis), bevacizumab (Avastin), and faricimab (Vabysmo), are administered by injection in the physician's office. Medicare Part B covers drugs that are administered by a physician as part of a covered medical service. Because these drugs require a physician to perform the injection during a clinical visit, they fall under Part B rather than Part D, even though they are technically pharmaceutical products. This distinction matters significantly for cost-sharing purposes.

What the injections cost under Part B

After the Part B deductible, Medicare pays 80% of the Medicare-approved amount for the drug and the associated physician service. You pay 20%. The Medicare-approved amount for these drugs varies significantly. Avastin (bevacizumab) is an off-label compounded preparation that costs roughly $50 to $100 per injection at approved rates. Eylea and Lucentis have much higher approved rates, often $1,500 to $2,000 or more per injection. At 20% of $2,000, a single injection costs you $400 without supplemental coverage. Monthly injections, the typical initial treatment frequency, would mean $4,800 per year in out-of-pocket costs on that drug alone.

How Medigap changes the calculation

Medigap Plan G or Plan N covers the 20% Part B coinsurance for AMD injections. With Plan G, after you pay the annual Part B deductible, your share of every AMD injection is $0. The same treatment that costs $400 per injection without supplemental coverage costs nothing with Plan G in place. For patients receiving monthly AMD injections on an ongoing basis, the annual Medigap premium is typically far less than what they would pay in 20% coinsurance without it. This is one of the clearest illustrations of when Medigap pays for itself quickly.

Avastin versus Eylea versus Lucentis

Bevacizumab (Avastin) is a cancer drug used off-label for AMD at a fraction of the cost of purpose-built AMD drugs. Clinical evidence generally supports similar effectiveness, and Medicare covers it when used for AMD. The choice of which anti-VEGF agent to use is a clinical decision between you and your ophthalmologist. For cost-sharing purposes under Medicare, the choice affects what you pay, 20% of $75 versus 20% of $2,000 is a substantial difference if you lack supplemental coverage. With Medigap, your out-of-pocket is $0 regardless of which agent is used.

Monitoring and diagnostic testing

Regular monitoring for AMD includes optical coherence tomography imaging, fluorescein angiography, and routine ophthalmology visits. These diagnostic services are covered under Part B with standard cost-sharing. The ophthalmology visits related to AMD treatment and monitoring are distinct from routine eye exams, which Original Medicare does not cover. If your ophthalmologist visit includes evaluation and management of AMD specifically, it is a covered diagnostic visit, not a routine eye exam.

Medicare Advantage and AMD treatment

Medicare Advantage plans cover AMD injections to the same extent as Original Medicare. However, prior authorization may be required for the specific drug used, and some plans have preferred agents or step therapy requirements that could affect which drug is covered first. Verify your plan's coverage for the specific anti-VEGF agent your ophthalmologist uses before beginning treatment. If you develop AMD while in a Medicare Advantage plan and the prior authorization or drug restrictions create problems, understanding your appeal rights is important.

Bryce Casson

Licensed Independent Medicare Broker

Bryce Casson is an independent Medicare insurance broker who works with every major carrier. He does not represent any single insurer, which means his recommendations are based on what actually fits each client's situation, not on commissions or quotas.